Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
12.66
-0.57 (-4.31%)
At close: Aug 31, 2026, 4:00 PM EDT
12.60
-0.06 (-0.47%)
After-hours: Aug 31, 2026, 7:36 PM EDT
Evommune Revenue
Evommune had revenue of $10.00M in the twelve months ending June 30, 2026, up 233.33% year-over-year. In the year 2025, Evommune had annual revenue of $13.00M with 85.71% growth.
Revenue (ttm)
$10.00M
Revenue Growth
+233.33%
P/S Ratio
45.95
Revenue / Employee
$208,333
Employees
48
Market Cap
459.46M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.00M | 6.00M | 85.71% |
| Dec 31, 2024 | 7.00M | 2.00M | 40.00% |
| Dec 31, 2023 | 5.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
EVMN News
- 5 days ago - Evommune initiated with a Buy at Needham - TheFly
- 24 days ago - Evommune price target lowered to $29 from $30 at RBC Capital - TheFly
- 25 days ago - Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
- 25 days ago - Evommune Slides: Corporate presentation - Filings
- 25 days ago - Evommune Quarterly report: Q2 2026 - Filings
- 25 days ago - Evommune Earnings release: Q2 2026 - Filings
- 4 weeks ago - Evommune initiates Phase 2b trial of EVO756 - TheFly
- 4 weeks ago - Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis - Business Wire